Abstract:The objective of this study was to investigate the efficacy and safety of a novel paclitaxel-coated balloon catheter in the treatment of chronic atherosclerotic occlusive disease in femoropopliteal arteries. Patients with peripheral artery occlusive disease undergoing percutaneous transluminal angioplasty were prospectively randomized to novel carrier-free ZENFlow (Zhejiang Zylox Medical Device Co Ltd, Hangzhou, China) paclitaxel drug-coated balloon (DCB) group or plain balloon angioplasty (PBA) group. The primary end point was late lumen loss at 6 months assessed by blinded angiographic core laboratory quantitative analyses. Secondary end points included primary target vessel patency at 12 months, binary restenosis, target lesion revascularization, target vessel revascularization, Rutherford class change, and ankle-brachial index (ABI) at 6 months. There were 192 Chinese patients who were randomized in 15 hospitals (93 to DCB and 99 to PBA). The mean age of patients was 68 years; 71.9% were male, and 50.5% were smokers. No significant differences were identified between the groups in terms of baseline patient demographics, comorbidities, Rutherford class, and ABI. Mean lesion length was 62.5 mm; 12.7% had in-stent restenosis, and 37% of lesions were total occlusion. In total, 23 (12%) patients underwent bailout stenting because of flow-limiting dissection after balloon angioplasty. After 6 months, late lumen loss in the DCB and PBA groups was 0.80 ± 0.71 mm and 1.69 ± 0.87 mm (P < .0001), respectively. Primary target vessel patency rate was significantly higher in the DCB group than in the PBA group (54% vs 31.3%; P = .0091) at 12 months. Target vessel restenosis rate was dramatically lower in the DCB group than in the PBA group (16.3% vs 54.6%; P < .0001), as were target lesion revascularization (8.8% vs 27.1%; P = .052) and target vessel revascularization (11.8% vs 30%; P = .0086) at 6 months. Significant improvement in Rutherford class was found in the DCB group compared with the PBA group (P = .0385). Postoperative ABI was markedly increased in the DCB group than in the PBA group (0.89 ± 0.27 vs 0.78 ± 0.28; P = .0182) after 6 months. There were no definitely device-related deaths or major adverse events in either group. Balloon angioplasty using the ZENFlow DCB catheter is a safe and effective method for the treatment of chronic occlusive lesions in the femoropopliteal artery and can achieve satisfactory early and midterm outcomes compared with regular balloon angioplasty.

An ultralow dose paclitaxel coated drug balloon with an outer protective sheath for peripheral arterial disease treatment

Acotec Drug-Coated Balloon Catheter

In vitro evaluation of nanoparticle drug-coated balloons: a pectin-RGDS-OC8H17-paclitaxel solution

Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients

Ultrasound controlled paclitaxel releasing system—A novel method for improving the availability of coronary artery drug coated balloon

Comparative Evaluation of Local and Downstream Responses in Two Commercially Available Paclitaxel-Coated Balloons in Healthy Peripheral Arteries of a Swine Model

Drug-Coated Balloons: Drugs Beyond Paclitaxel?

Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine

Drug Release and Biocompatibility of a Paclitaxel-Coated Balloon Prepared Using the Electrostatic Spray Method

Evaluation of a new paclitaxel-coated balloon catheter in an in vivo porcine peripheral venous model: Feasibility, safety, and drug deliverability

Pressure-responsive pH-triggered layer-by-layer coating of paclitaxel-eluting balloon catheters for instant high-dose drug delivery for percutaneous coronary artery intervention

Drug-loaded Balloon with Built-in NIR Controlled Tip-Separable Microneedles for Long-Effective Arteriosclerosis Treatment.

Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics.

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Nanoparticle coatings for controlled release of quercetin from an angioplasty balloon.

TCTAP A-002 Paclitaxel-coated Balloon Versus Paclitaxel-eluting Stent for the Treatment of Diffuse DES In-stent Restenotic Lesions: A Substudy of PEPCAD China ISR Trial

A Multicenter Randomized Trial Assessing ZENFlow Carrier-Free Drug-Coated Balloon for the Treatment of Femoropopliteal Artery Lesions

Efficacy and Safety of Dual Paclitaxel and Sirolimus Nanoparticle-Coated Balloon

Mir-22-incorporated Polyelectrolyte Coating Prevents Intima Hyperplasia after Balloon-Induced Vascular Injury.

Drug-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Hemodialysis Fistulae

LEA 35. Randomized, Multicenter Trial of ZENFlow Drug-Eluting Balloon in the Treatment of Femoropopliteal Artery Occlusive Disease